Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL1107 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BL1107 is sterile ophthalmic solution to be administered at varying concentrations | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BL1107 | DRUG | BL1107 topical ocular solution |
Inclusion Criteria: * Documented diagnosis of dry eye disease * Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis Exclusion Criteria: * Any active ocular disease * Anticipated wearing of contact lenses during study Additional criteria per protoco...
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-319 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Bausch Health Companies Inc. | BHC | 1 | PHASE2 | BL1107 |
BL1107 is an investigational small molecule being developed for the treatment of Dry Eye Disease. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is intended to address symptoms associated with this ophthalmic condition.
BL1107 targets the alpha-2B adrenergic receptor. By acting on this receptor, the drug is being studied for its potential effects in treating Dry Eye Disease. The specific mechanism of action is under investigation in clinical trials.
BL1107 is being developed by Bausch Health Companies Inc., which trades under the ticker symbol BHC. The company is conducting clinical research on this investigational drug for Dry Eye Disease.
BL1107 is in Phase 2 clinical development. It is an investigational drug and has not yet received FDA approval. The ongoing Phase 2 trial is designed to evaluate the drug's effects in patients with Dry Eye Disease.
BL1107 is being studied in a Phase 2 clinical trial with the identifier NCT0777888. The trial is titled 'BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial' and is currently not yet recruiting participants. The study plans to enroll 20 patients with Dry Eye Disease.